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to end up paying more in debt servicing than before
they received their debt relief. This is because such
countries are currently repaying debt to the World
Bank and International Monetary Fund while repay-
ments to creditor nations under bilateral agreements
are not being honoured. When the World Bank and
International Monetary Fund debts are cancelled
under the initiative, this will release cash reserves and
oblige those countries to start repaying creditor
countries. And, as if proving the cynics right, Uganda’s
benefit has been short lived: a fall in coffee prices has
rendered Uganda’s debt unsustainable again—only 10
months after it received assistance under the heavily
indebted poor countries initiative.10
Earlier this year Jubilee 2000’s campaign cajoled a
positive response from the governments of Britain,
Canada, Germany, and the United States, as well as
encouraging noises from the World Bank and
International Monetary Fund. But recent reports indi-
cate that the world’s poor are likely to be disappointed
when the G8 countries meet in Cologne next week.11
The International Monetary Fund is leading the
campaign to draw back from the extent of debt relief
that some of the G8 countries had been promising. It is
offering a three year wait for debt relief rather than six,
but countries still have to maintain structural
adjustments for six years, with reapplication of the debt
if they fail.
Cancelling debt for the world’s poorest people is a
fitting way to welcome the new millennium. The
world’s richest finance ministers should seize the
opportunity when they meet next week. The rest of us
should join the many worldwide events that Jubilee
2000 is holding between now and the G8 meeting in
Cologne—for example, on 13 June supporters of debt
cancellation will be linking arms across the River
Thames in London. As the playwright Harold Pinter
put it: “It’s actually a state of war. The powerful against
the rest.”12 Let’s end the war and set the slaves free.
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Nutritional hyperhomocysteinaemia
Evidence mounts for its role in vascular disease
A
raised concentration of serum homocysteine is
increasingly being implicated as a risk factor
for clinical vascular disease. It is known to be
injurious to the vascular endothelium in animals,1 and
many reports have now confirmed the presence of
raised homocysteine concentrations in patients with
peripheral vascular disease, myocardial infarction,
stroke, and venous thromboembolism. Indeed, moder-
ate and intermediate increases in homocysteine
concentration have been found in up to 40% of
patients with vascular disease2 and in up to 35% of
patients with venous thromboembolism.3 The obvious
question is: is this cause or effect? And, if it is causal,
should we be screening for and treating hyperhomo-
cysteinaemia?
All circulating homocysteine is derived from
methionine in the diet, and it is removed by either
remethylation to methionine or conversion to cysteine
via a transsulphuration pathway. Classic homocystinu-
ria, a rare autosomal recessive condition, of which pre-
mature vascular disease and thrombosis are major
features, is the result of a deficiency of the enzyme for
transsulphuration, cystathione ß-synthetase. The het-
erozygous state for cystathione ß-synthetase deficiency
occurs in 1 in 70 to 1 in 200 of the general population4
and is associated with moderate increases in serum
homocysteine. More common, but less severe, genetic
changes in enzymes implicated in the remethylation
pathway (methylene tetrahydrofolate reductase and
methionine synthetase) may also be responsible for
milder increases in homocysteine concentrations
(above 15 ìmol/l). Genetic mutation of methylene tet-
rahydrofolate reductase shows geographical variations.
A thermolabile variant of methylene tetrahydrofolate
reductase is extremely common in North America,
with an overall allele frequency of 38% in the general
population.5 Nevertheless, it is thought to result in
hyperhomocysteinaemia only in the presence of folate
deficiency.5
Early reports focused on premature vascular
disease in young patients without classical risk factors.
A high proportion of these patients have cystathione
ß-synthetase deficiency and other enzyme abnormali-
ties. Genetic abnormalities, however, cannot account
for the frequency of raised blood homocysteine
concentrations (hyperhomocysteinaemia) seen in the
wider population of patients with vasculardisease, and
attention is now being focused on diet induced hyper-
homocysteinaemia as a cause of increased vascular
risk, probably acting synergistically with more conven-
tional risk factors.6 Essential cofactors for the enzymes
of homocysteine metabolism (vitamin B-6, vitamin
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B-12, and folic acid) are acquired only from the diet.
The active form of vitamin B-6 (pyridoxal phosphate)
serves as the cofactor for two successive steps of the
transsulfuration pathway; and the active forms of
vitamin B-12 and folic acid serve as cofactor
(methylcobalamin) and cosubstrate (methyltetrahydro-
folate), respectively, for the enzymes in the remethyla-
tion pathway.4
Nutritional studies in patients with vascular disease
and controls have shown an inverse correlation between
concentrations of vitamin B-12 and folate and those of
homocysteine.7 Selhub et al found that 40% of the
elderly population was deficient in folate,8 and in
patients with subnormal levels of folate 84% had raised
homocysteine concentrations. The correlation between
B-6 deficiency and raised homocysteine concentrations
is less clear, but as the population with vascular disease is
likely to have other risk factors, including smoking, it is
interesting to note that smokers have a significantly
lower vitamin B-6 level than non-smokers.9
Irrespective of its cause, moderate and intermedi-
ate hyperhomocysteinaemia is readily correctable by
folate, betaine, or vitamin supplementation. Homo-
cysteine concentrations in folate deficient patients can
be normalised by folic acid supplementation,7 which
increases the availability of the cosubstrate, methyl-
tetrahydrofolate, and drives the pathway for homo-
cysteine remethylation. The effective dose of supple-
mentation has not yet been determined, but maximal
therapeutic effect is seen with doses over 400 mg and
after four to six weeks.10 Betaine serves as an alternative
methyl donor to folic acid in the recycling of
homocysteine to methionine. Vitamin B-12 normalises
homocysteine concentrations in patients who are vita-
min B-12 deficient but not in normal subjects.11
Vitamin B-6 alone does not reduce plasma homo-
cysteine concentrations,11 but when it was administered
in combination with folic acid homocysteine concen-
tration was lowered by 50%.7 Elderly patients taking
vitamin B-6 supplements of 100-200 mg/day showed a
73% reduction in the risk of angina and myocardial
infarction, with an average increase in lifespan of eight
(range 7-17) years.12
Thus homocysteine seems likely to be a risk factor,
interacting with other risk factors, applicable to all
patients with vascular disease and not just those with
premature disease. It seems logical to assume that a
reduction in homocysteine concentration will reduce
the risk of atherosclerotic lesions and thrombosis, but
there are as yet no published data to prove this. The
potential impact of treating a diet induced risk factor
for atherosclerosis is enormous: such treatment is safe
and inexpensive and does not inhibit lifestyle. It is time
for clinical trials to determine the impact of treatment
to reduce homocysteine concentrations on the
subsequent course of vascular disease.
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Clinical Evidence
This month sees the publication of a new resource for clinicians
T
his week’s BMJ carries a sample of information
from a new resource for clinicians, Clinical Evi-
dence, which will be launched later this month
(p 1600). The inspiration for Clinical Evidence came in a
phone call in 1995. Tom Mann and his colleagues at
the NHS Executive asked the BMJ to explore the possi-
bility of developing an evidence “formulary” along the
lines of the British National Formulary. They recognised
that clinicians were under increasing pressure to keep
up to date and to base their practice more firmly on
evidence but that few had the necessary time or skills to
do this. Their idea was to provide a pocket-size book
containing concise and regularly updated summaries
of the best available evidence on clinical interventions.
A small team at the BMJ set to work. In partnership
with the American College of Physicians we convened
an international advisory board, held focus groups of
clinicians, talked to patient support groups, and
adopted countless good ideas from early drafts by our
contributors. Throughout we kept in mind an equation
set out by Shaughnessey et al.1 This states that the use-
fulness of any source of information is equal to its rel-
evance multiplied by its validity, divided by the work
required to extract the information. To be as useful as
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• Correction  
Nutritional hyperhomocysteinaemia 
This editorial by Mohan and Stansby (12 June, pp 1569-70) contained an error in the dose given for folic acid supplementation. The 
third sentence of the fifth paragraph should have read: “The effective dose of supplementation has not yet been determined, but 
maximal therapeutic effect is seen with doses over 400 µg [not 400 mg] and after four to six weeks.” 
 
